Argenx Se (ARGX) Current Taxes (2017 - 2026)
Argenx Se's (ARGX) quarterly Current Taxes came in at $49.0 million in Q2 2026, down 99.73% YoY from $18.2 billion in Q2 2025, and up 16.67% on a QoQ basis from $42.0 million in Q4 2025.
Argenx Se (ARGX) Current Taxes (2017 - 2026) Analysis & Trends
Argenx Se (ARGX) has 10 years of Current Taxes data on file, last reported at $49.0 million in Q2 2026.
- Quarterly Current Taxes fell 99.73% year-over-year to $49.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $49.0 million (down 99.73% YoY) and the FY2025 annual result came in at $42.0 million, up 213.67% from the prior year.
- Current Taxes climbed to $49.0 million in Q2 2026, from $42.0 million in the prior quarter.
- In the past five years, Current Taxes ranged from a high of $18.2 billion in Q2 2025 to a low of $3.2 million in Q4 2022.
- A 5-year average of $2.0 billion and a median of $13.4 million in 2024 frame the typical range for Current Taxes.
- Annual changes were most pronounced in 2025 — Current Taxes surged 130107.21% — and 2026, when it plunged 99.73%.
- Tracing ARGX's Current Taxes over 5 years: stood at $3.2 million in 2022, then soared by 36.25% to $4.3 million in 2023, then soared by 208.95% to $13.4 million in 2024, then jumped by 213.67% to $42.0 million in 2025, then rose by 16.67% to $49.0 million in 2026.
- The last three Current Taxes figures came in at $49.0 million (Q2 2026), $42.0 million (Q4 2025), and $18.2 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 49.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 76.32 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 59,089.99 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 74.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.00 Mn |
| Dec 31, 2025 | 42.00 Mn |
| Jun 30, 2025 | 18.16 Bn |
| Dec 31, 2024 | 13.39 Mn |
| Jun 30, 2024 | 13.95 Mn |
| Dec 31, 2023 | 4.33 Mn |
| Jun 30, 2023 | 4.61 Mn |
| Dec 31, 2022 | 3.18 Mn |
| Jun 30, 2022 | 3.42 Mn |
| Dec 31, 2021 | 4.32 Mn |
| Jun 30, 2021 | 1.15 Mn |
| Dec 31, 2020 | 3.40 Mn |
| Jun 30, 2020 | 474,729.32 |
| Dec 31, 2019 | 380,769.36 |
| Jun 30, 2019 | 424,735.58 |
| Dec 31, 2018 | 939,369.26 |
| Jun 30, 2018 | 674,296.09 |
| Dec 31, 2017 | 702,927.22 |
| Jun 30, 2017 | 656,430.94 |